Akums Drugs Q1 Profit Jumps 57.5% to Rs 100 Cr; Stock Surges
Infographic: Akums Drugs Shares Surge 5% on 57.5% Q1 Profit Jump to Rs 100 Crore
Key Highlights
Akums Drugs & Pharmaceuticals reports a 57.5% year-on-year Q1 net profit increase to Rs 100 crore, driving its stock up over 5%. Revenue and EBITDA also saw significant growth.
Akums Drugs and Pharmaceuticals recorded a significant intraday stock surge of more than 5% today, driven by its robust financial performance in the first quarter.
The pharmaceutical company announced its consolidated net profit increased by 57.5% year-on-year, reaching Rs 100 crore. This profit growth substantially outpaced the 13.9% rise in revenue from operations, which stood at Rs 1,167 crore for the quarter.
Key Q1 Financials
- : Up 57.5% to Rs 100 crore.
- from Operations: Increased 13.9% to Rs 1,167 crore.
- Consolidated : Rose 35.5% to Rs 175 crore.
- EBITDA Margin: Expanded to 15% from 12.6% year-on-year.
The company’s operational efficiency notably improved, as evidenced by its consolidated EBITDA margin expanding from 12.6% in the previous year to 15%. This margin growth underscores effective cost management and stronger profitability.
Stock Performance Overview
- Intraday Gain: More than 5%.
- Six-Month Return: Delivered 57%.
- 2026 Rally: Achieved 64%.
- Current Trading Price: Rs 732 apiece on the .
Akums Drugs and Pharmaceuticals shares are currently trading at Rs 732 apiece on the NSE. The strong quarterly results have fueled investor confidence, with the stock delivering a 57% return over the past six months and a 64% rally in 2026.